Venrock Healthcare Capital Partners

Venrock Healthcare Capital Partners led CellCentric's £170m Series D in May 2026 — cited as Europe's largest biotech round of the year — alongside co-investors including Pfizer, Fidelity, Sofinnova Partners, and the American Cancer Society's BrightEdge venture vehicle. The round will fund CellCentric's Phase III clinical programme for inobrodib, a first-in-class p300/CBP histone acetyltransferase inhibitor targeting relapsed multiple myeloma and castrate-resistant prostate cancer.

Venrock Healthcare Capital Partners is the life-sciences-dedicated vehicle of Venrock, the storied venture firm founded in 1969 as the venture investing Arm of the Rockefeller family. The healthcare fund focuses on late-stage clinical-stage biotechnology and therapeutics, typically writing Series B through growth-equity cheques. Its portfolio has included companies across oncology, immunology, and rare disease. The parent Venrock firm — historically associated with early investments in Apple and Intel — has progressively concentrated its healthcare allocation through this dedicated vehicle.

The CellCentric co-lead signals Venrock Healthcare's continued appetite for UK and European oncology assets at the clinical stage. For CellCentric, headquartered in Cambridge, securing a Rockefeller-lineage lead investor alongside a pharmaceutical strategic (Pfizer) provides both capital validation and a credible route-to-market signal as it advances toward pivotal trial readouts.